Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E5DP
|
|||
| Former ID |
DNCL002705
|
|||
| Drug Name |
Cixutumumab
|
|||
| Synonyms |
LY3012217
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 2 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 2 | [1] | ||
| Company |
Lilly
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01232452) A Study in Non-Small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.